Guangzhou-based medical device giant Burning Rock (NASDAQ: BNR) has announced a strategic partnership with AstraZeneca (AZ, NASDAQ: AZN). The collaboration will utilize Burning Rock’s world-leading testing technology and high-quality, standardized testing capacities to develop and commercialize companion diagnostics (CDx) products for AstraZeneca’s breast cancer and prostate cancer therapies. Financial details of the agreement have not been disclosed.
Burning Rock’s Advanced Technology and Global Reach
Burning Rock, known for its advanced next-generation sequencing research and development and testing technology, operates central laboratories in both the US and China. The company also has a global CDx regulatory pipeline, positioning it as a key player in the development of diagnostic tools that complement cancer treatments.
Enhancing Cancer Treatment with Companion Diagnostics
The partnership with AstraZeneca aims to enhance the precision and effectiveness of breast and prostate cancer therapies through the use of companion diagnostics. These diagnostics are critical in personalized medicine, as they help identify patients who are most likely to respond to specific treatments, thereby improving outcomes and reducing unnecessary side effects.-Fineline Info & Tech
